Volume 23, Issue 3 , Pages 178-184, May 2009
Increased urinary levels of CXCL5, CXCL8 and CXCL9 in patients with Type 2 diabetic nephropathy☆
Abstract
CXC chemokines are particularly significant for leukocyte infiltration in inflammatory diseases. Recent reports have shown that inflammation is one of potential pathogenic mechanisms for diabetic nephropathy. However, information on inflammation related with CXC chemokines in human Type 2 diabetic nephropathy still remains scarce. We measured urinary and serum levels of three CXC chemokines, CXCL5, CXCL8 and CXCL9, in 45 Type 2 diabetic patients (DM), 42 primary renal disease (PRD) patients and 22 healthy controls by enzyme-linked immunosorbent assay. Urinary levels of CXCL5, CXCL8 and CXCL9 in DM were significantly elevated compared to those in controls (P<.0001, P<.01, P<.001; respectively). They increased consistent with urinary albumin excretion rate (UAER) and correlated with UAER in partial correlation analyses (r=0.41, P<.01; r=0.40, P<.01; r=0.45, P<.01; respectively). Urinary levels of CXCL5 in DM were significantly interrelated to HbA1c (r=0.42, P<.01). On the other hand, PRD showed significant increased levels of urinary CXCL8 and CXCL9 compared to controls (P<.001, P<.01; respectively), and so did PRD as UAER increased. However, there were no significant elevations of urinary levels of CXCL5 in PRD in spite of the increased UAER. We found significant associations of UAER in DM with diabetes duration, 1/serum creatinine, urinary CXCL5 (adjusted R2=0.67, P<.0001) or CXCL9 (adjusted R2=0.69, P<.0001) in a stepwise multiple regression analysis. These results suggest that these three CXC chemokines may be involved in the progression of human Type 2 diabetic nephropathy and that CXCL5 may be of use for telling diabetic nephropathy from primary renal diseases.
Keywords: Diabetic nephropathy, Inflammation, CXC chemokine
To access this article, please choose from the options below
☆ This work was supported by a Health and Labour Science Research Grant for Clinical Research in Evidenced Based Medicine (0209001) from the Ministry of Health, Labour and Welfare of Japan. A portion of this study was presented by Mayumi Higurashi in the poster presentation entitled “Involvement of Activated Macrophages in the Development of Diabetic Nephropathy” at the Renal Week 2003 Meeting, San Diego, CA, USA, November 14–17, 2003.
PII: S1056-8727(07)00147-X
doi:10.1016/j.jdiacomp.2007.12.001
© 2009 Elsevier Inc. All rights reserved.
Volume 23, Issue 3 , Pages 178-184, May 2009
